Cargando…

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19

OBJECTIVE: To evaluate the clinical consequences of extended interval dosing (EID) of ocrelizumab in relapsing-remitting multiple sclerosis (RRMS) during the coronavirus disease 2019 (COVID-19) pandemic. METHODS: In our retrospective, multicenter cohort study, we compared patients with RRMS on EID (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rolfes, Leoni, Pawlitzki, Marc, Pfeuffer, Steffen, Nelke, Christopher, Lux, Anke, Pul, Refik, Kleinschnitz, Christoph, Kleinschnitz, Konstanze, Rogall, Rebeca, Pape, Katrin, Bittner, Stefan, Zipp, Frauke, Warnke, Clemens, Goereci, Yasemin, Schroeter, Michael, Ingwersen, Jens, Aktas, Orhan, Klotz, Luisa, Ruck, Tobias, Wiendl, Heinz, Meuth, Sven G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362352/ https://www.ncbi.nlm.nih.gov/pubmed/34261812 http://dx.doi.org/10.1212/NXI.0000000000001035

Ejemplares similares

Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab
por: Pfeuffer, Steffen, et al.
Publicado: (2023)

Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Ocrelizumab initiation in patients with MS: A multicenter observational study
por: Ellwardt, Erik, et al.
Publicado: (2020)

Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment
por: Rolfes, Leoni, et al.
Publicado: (2021)

Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine
por: Rolfes, Leoni, et al.
Publicado: (2023)

Comparing Plasma Exchange to Escalated Methyl Prednisolone in Refractory Multiple Sclerosis Relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2019)

Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Rolfes, Leoni, et al.
Publicado: (2020)

Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Huntemann, Niklas, et al.
Publicado: (2021)

Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab
por: Räuber, Saskia, et al.
Publicado: (2022)

Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosis
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells
por: Ruck, Tobias, et al.
Publicado: (2018)

Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis
por: Eschborn, Melanie, et al.
Publicado: (2021)

Comparative effectiveness of natalizumab versus ocrelizumab in multiple sclerosis: a real-world propensity score–matched study
por: Pape, Katrin, et al.
Publicado: (2022)

Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs—A Systematic Review
por: Rolfes, Leoni, et al.
Publicado: (2019)

Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2022)

The Innate Immune Response Characterizes Posterior Reversible Encephalopathy Syndrome
por: Nelke, Christopher, et al.
Publicado: (2021)

Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials
por: Ingwersen, J., et al.
Publicado: (2023)

NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study: Serum NfL predicts relapse-free progression
por: Uphaus, Timo, et al.
Publicado: (2021)

Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab
por: Räuber, Saskia, et al.
Publicado: (2022)

Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study
por: Ruck, Tobias, et al.
Publicado: (2019)

Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis
por: Regner-Nelke, Liesa, et al.
Publicado: (2022)

Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination
por: Rolfes, Leoni, et al.
Publicado: (2019)

Immune Checkpoint Inhibition–Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade
por: Nelke, Christopher, et al.
Publicado: (2023)

Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation
por: Rolfes, Leoni, et al.
Publicado: (2021)

Generation of a Model to Predict Differentiation and Migration of Lymphocyte Subsets under Homeostatic and CNS Autoinflammatory Conditions
por: Gross, Catharina C., et al.
Publicado: (2020)

Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment
por: Schönfelder, Kristina, et al.
Publicado: (2021)

NK Cell Patterns in Idiopathic Inflammatory Myopathies with Pulmonary Affection
por: Pawlitzki, Marc, et al.
Publicado: (2021)

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
por: Rolfes, Leoni, et al.
Publicado: (2019)

Merits and culprits of immunotherapies for neurological diseases in times of COVID-19
por: Pawlitzki, Marc, et al.
Publicado: (2020)

Risiken und Chancen von Immuntherapien in Zeiten der Coronavirus-2019-Pandemie
por: Pawlitzki, Marc, et al.
Publicado: (2020)

A fatal case of daclizumab-induced liver failure in a patient with MS
por: Stettner, Mark, et al.
Publicado: (2019)

Ineffective treatment of PML with pembrolizumab: Exhausted memory T-cell subsets as a clue?
por: Pawlitzki, Marc, et al.
Publicado: (2019)

Impact of NKG2D Signaling on Natural Killer and T‐Cell Function in Cerebral Ischemia
por: David, Christina, et al.
Publicado: (2023)

Natural Killer Cells Are Present in Rag1(−/−) Mice and Promote Tissue Damage During the Acute Phase of Ischemic Stroke
por: Rolfes, Leoni, et al.
Publicado: (2021)

MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation
por: Loos, Julia, et al.
Publicado: (2020)

Two pore domain potassium channels in cerebral ischemia: a focus on K(2P)9.1 (TASK3, KCNK9)
por: Ehling, Petra, et al.
Publicado: (2010)

Correction: Two pore domain potassium channels in cerebral ischemia: a focus on K2P9.1 (TASK3, KCNK9)
por: Ehling, Petra, et al.
Publicado: (2013)

ALAIN01—Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential
por: Ruck, Tobias, et al.
Publicado: (2016)

Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients—Lessons Learned From SARS and MERS
por: Möhn, Nora, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nn09qnl577fhbkfs4p165tch6l